RLYB212
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for RLYB212, covering 2026-03-06 to 2026-03-06. Get the full timeline:
Most recent: Clinical Trial Update: Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization [Phase 2]